帕罗西汀治疗脑卒中后抑郁临床观察

目的探讨帕罗西汀治疗脑卒中后抑郁的临床疗效和安全性。方法将符合标准的80例患者随机分为观察组和对照组各40例,观察组给予口服帕罗西汀,对照组给予口服养血清脑颗粒,疗程均为8周。疗程结束后采用24项汉密尔顿抑郁量表(HAMD-24)和Barthel指数(BMI)评价临床疗效。结果 2组患者治疗后,抑郁程度和日常生活能力均得到明显改善(P<0.01),观察组改善幅度更大(P<0.01);观察组患者抑郁治疗总有效率为90.00%,明显高于对照组的65.00%(P<0.01)。结论帕罗西汀治疗脑卒中后抑郁具有较好的临床效果,安全性高,值得临床推广应用。

The clinical study of Paroxetine in the treatment of post-stroke depression

Objective To explore clinical effectiveness and safty of paroxetine in the treatment of post-stroke depression.Methods 80 patients were divided randomly into observation group(40 cases) and control group(40 cases).The observation group was treated with paroxetine,and the control group was treated with Yangxueqingnao particles for 8 weeks,then evaluate clinical effectiveness with HAMD-24 and BMI.Results After treatment,the severity of depression and activities of daily living were significantly improved(P<0.01),and the observation group improved substantially greater(P<0.01).The effective rate of the observation group(90.00%) was higher than that of the control group(65.00%),and the discrepancy are statistically significant(P<0.01).Conclusion It is worthy of clinical application of paroxetine to treat post-stroke depression because of the advantages of high clinical effects and safty.